Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-225230
AMENDMENT NO. 2 DATED NOVEMBER 12, 2020
PROSPECTUS SUPPLEMENT DATED JULY 17, 2019
(To the Prospectus Dated June 13, 2018)
Up to $31,716,138
This Amendment No. 2 to Prospectus Supplement (this “Amendment”)
amends and supplements the information in our prospectus supplement
dated July 17, 2019 (the “Prospectus Supplement”) and the
accompanying prospectus dated June 13, 2018 (the “Prospectus”).
This Amendment should be read in conjunction with the Prospectus
Supplement and the accompanying Prospectus, and is qualified by
reference thereto, except to the extent that the information herein
amends or supersedes the information contained in the Prospectus
Supplement or the accompanying Prospectus. This Amendment is not
complete without, and may only be delivered or utilized in
connection with, the Prospectus Supplement, the accompanying
Prospectus, and any future amendments or supplements hereto or
We filed the Prospectus Supplement in connection with that certain
Sales Agreement, dated July 17, 2019 (the “Sales Agreement”), by
and between SVB Leerink LLC (“SVB Leerink”), acting as the agent,
and us. Since July 17, 2019, we have sold an aggregate of 914,735
shares of our common stock pursuant to the Sales Agreement with an
aggregate sales price of $8,283,862. Consequently, up to
$31,716,138 remains available for sale by us under the Sales
On March 23, 2020, we filed Amendment No. 1 to the Prospectus
Supplement (the “March 2020 Amendment”) indicating that we were, at
that time, subject to General Instruction I.B.6 of Form S-3, which
limited the amounts that we were able sell under the registration
statement of which the March 2020 Amendment, the Prospectus, the
Prospectus Supplement and this Amendment form a part. We are
currently no longer subject to the limitations under General
Instruction I.B.6 of Form S-3 and, therefore, in accordance with
the terms of the Sales Agreement, we may offer and sell shares of
our common stock having an aggregate offering price of up to
$31,716,138 from time to time through SVB Leerink.
Our common stock is listed on the Nasdaq Capital Market under the
Investing in our common stock involves a high degree of risk.
See “Risk Factors” contained in the documents we incorporate by
reference in this Prospectus Supplement to read about factors you
should consider before investing in our securities.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or determined if this prospectus supplement and the
accompanying prospectus is truthful or complete. Any representation
to the contrary is a criminal offense.
The date of this Amendment No. 2 to Prospectus Supplement is
November 12, 2020.